Analysis of efficacy and adverse effects of entecavir in the treatment of decompensate cirrhosis patients with chronic hepatitis B
10.3760/cma.j.issn.1008-6706.2017.24.006
- VernacularTitle:恩替卡韦治疗乙肝后肝硬化失代偿期的疗效及不良反应分析
- Author:
Zhizhen YE
1
;
Wei WANG
Author Information
1. 浙江省人民医院杭州医学院附属人民医院药剂科
- Keywords:
Liver cirrhosis;
Hepatitis B,chronic;
Entecavir
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(24):3701-3704
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and adverse effects of entecavir in the treatment of decompensate cirrhosis patients with chronic hepatitis B.Methods 80 decompensate cirrhosis patients with chronic hepatitis B were selected as the research subjects.The patients were randomly divided into two groups according to the digital table.The control group was given conventional treatment,and the observation group was treated with entecavir on the basis of conventional treatment.The hepatitis B virus deoxyribonucleic acid (HBV-DNA) changes,the changes of liver function,the incidence ofadverse reactions were compared between the two groups.Results Before treatment,the HBV-DNA,ALT and AST levels had no significant differences between the two groups (all P ＞ 0.05).After treatment for 4,12,24 and 48 weeks,the levels of HBV-DNA,ALT and AST of the observation group and the control group were significantly lower than those before treatment (all P ＜ 0.05),which of the observation group were significantly lower than those of the control group (all P ＜ 0.05).The incidence rate of adverse reaction of the observation group was 17.5％,which was significantly lower than 40.0％ of the control group,the difference was statistically significant(x2 =8.345,P ＜0.05).Conclusion The entecavir can effectively reduce the level of HBV-DNA,improve liver function and without significant adverse effects in treating decompensate cirrhosis patients with chronic hepatitis B.
